Amivantamab (Rybrevant) + Carboplatin + Pemetrexed Treatment Protocol

Amivantamab (Rybrevant), carboplatin and pemetrexed form an FDA-approved first-line combination of chemotherapy and targeted treatment for advanced non-small cell lung cancer (NSCLC) with an EGFR exon 20 insertion mutation.

Amivantamab (Rybrevant)

• Class: Bispecific monoclonal antibody
• Targets: EGFR (epidermal growth factor receptor) and MET
• Mechanism of Action: Binds EGFR and MET receptors to stop tumor growth and cell proliferation. Activates immune cells to help destroy tumor cells.
• Characteristics: Effective in NSCLC with EGFR exon 20 insertion mutations. Infusion reactions are common; antihistamine and steroid premedication is required.
• Administration: Intravenous (IV), weekly or every two weeks (maintenance)

Carboplatin

• Class: Platinum-derived alkylating chemotherapy agent
• Mechanism of Action: Cross-links DNA, stopping cell division and inducing apoptosis (programmed cell death).
• Characteristics: Used as an alternative to cisplatin because of its low hematologic toxicity risk. Dosing is generally based on AUC (area under the curve), commonly AUC 5.
• Adverse Effects: Neutropenia, thrombocytopenia, anemia, nausea-vomiting
• Administration: IV infusion every 21 days

Pemetrexed (Alimta)

• Class: Antimetabolite (folate antagonist)
• Mechanism of Action: Inhibits intracellular folate-dependent enzymes, disrupting DNA and RNA synthesis and preventing proliferation.
• Characteristics: Generally used in nonsquamous NSCLC. Given with folic acid and vitamin B12 to reduce toxicity. Dexamethasone premedication is recommended to reduce skin rash risk.
• Adverse Effects: Fatigue, anemia, neutropenia, mucositis, nausea-vomiting
• Administration: IV infusion every 21 days (induction and maintenance)

Treatment Goals

For advanced NSCLC with an EGFR exon 20 insertion mutation:

• Stop tumor growth: Amivantamab blocks EGFR and MET signaling, preventing tumor cell growth and proliferation.
•  Reduce tumor burden with chemotherapy: Cytotoxic drugs such as carboplatin and pemetrexed directly kill cancer cells to shrink tumor mass.
• Control resistant tumors with targeted treatment: EGFR exon 20 insertion mutations resist conventional EGFR inhibitors (erlotinib, gefitinib, etc.). Amivantamab is specifically active against these mutations.
• Delay progression and extend survival: In clinical trials, this triple combination extended progression-free survival and increased objective response rates in some patients.
• Achieve long-term control while preserving quality of life: Monitor adverse effects to provide tolerable treatment appropriate to the patient's overall condition.

How Does Amivantamab (Rybrevant) + Carboplatin + Pemetrexed Work?

Carboplatin and pemetrexed are chemotherapy drugs designed to slow growth and kill cancer cells.

Amivantamab is a monoclonal antibody binding EGFR (epidermal growth factor receptor) and MET (mesenchymal-epithelial transition) receptors on lung cancer cells.

This binding:

• Blocks pathways signaling cancer cells to grow and divide.
• Also improves immune recognition, potentially enabling immune-mediated destruction of cancer cells.

Amivantamab is effective in patients with EGFR exon 20 insertion mutations, which may resist some other EGFR-targeted drugs.

Before treatment, FDA-approved genetic tests can determine whether a patient carries this mutation.

Treatment Indication

Advanced or Metastatic EGFR Exon 20 Insertion-Positive Nonsquamous NSCLC:

• Newly diagnosed,
• No previous systemic treatment,
• An EGFR exon 20 insertion mutation,
• Advanced (stage IV) or locally advanced disease unsuitable for curative surgery,
• Unsuitable for PD-(L)1 inhibitors,

May receive amivantamab + carboplatin + pemetrexed as first-line treatment.

Situations Unsuitable for Treatment

• Patients Without an EGFR Exon 20 Insertion Mutation: This treatment is effective only in patients carrying EGFR exon 20 insertion mutations. Patients without molecular confirmation are unsuitable for this protocol.
• History of Severe Hypersensitivity (Allergy): Strictly contraindicated with a history of severe hypersensitivity (anaphylaxis, severe infusion reaction) to amivantamab, carboplatin or pemetrexed.
• Severe Renal Impairment: Pemetrexed is renally eliminated. Use is not recommended if creatinine clearance is <45 mL/min.
• Severe Bone Marrow Failure: Carboplatin and pemetrexed are risky with severe neutropenia, thrombocytopenia or anemia. Delay treatment for active infections or sepsis.
• Active Autoimmune Disease or Immunosuppression: Amivantamab may have immune-mediated effects. Use caution with severe autoimmune disease (e.g., lupus, rheumatoid arthritis, myasthenia gravis) or immunosuppressive treatment.
• Pregnancy and Breastfeeding: This treatment may harm the embryo/fetus. It is contraindicated during pregnancy and breastfeeding. Effective contraception is essential during treatment and for a specified period afterward.
• Severe Cardiac Disease: Careful assessment is required with severe congestive heart failure, uncontrolled hypertension or active ischemic heart disease.

SGK Reimbursement Status

As of July 2025, amivantamab (Rybrevant) + carboplatin + pemetrexed is not yet reimbursed by SGK in Turkey. Carboplatin and pemetrexed are reimbursed for appropriate indications, but amivantamab is not.

Dosing Interval

Treatment is given in 21-day cycles. All drugs are combined for the first 4 cycles (induction), followed by amivantamab and pemetrexed alone (maintenance).

Amivantamab is weight-based: 1050 mg IV for patients below 80 kg and 1400 mg IV for those weighing 80 kg or more. The initial dose is generally divided over 2 days to reduce infusion reaction risk. Subsequent cycles may be given in a single day. During induction, it is administered every 21 days. Maintenance continues initially weekly, then every two weeks.

Carboplatin is dosed according to body surface area and kidney function. Generally, a single IV dose at AUC 5 is given every 21 days, only for the first 4 cycles (induction).

Pemetrexed is given at a fixed 500 mg/m² IV dose. It continues every 21 days with carboplatin and amivantamab during induction and with amivantamab alone during maintenance.

Precautions

Important Amivantamab Risks:

• Infusion Reactions: The most common adverse effect (particularly with the first dose). Fever, chills, hypotension or shortness of breath may develop. Premedication with antihistamines, antipyretics and steroids is mandatory. The initial infusion is generally split over two days and given slowly.
• Skin rash, acneiform eruption: May occur with EGFR inhibition, generally on the face and trunk. Topical or systemic treatment may be given if necessary.
• Hypomagnesemia and other electrolyte disturbances: Monitor magnesium, potassium and calcium and replace when needed.
• Pulmonary toxicity (rare): New cough or shortness of breath should prompt evaluation for interstitial lung disease.

Important Carboplatin Risks:

• Bone marrow suppression: Neutropenia, anemia and thrombocytopenia are among the most common adverse effects. Monitor blood counts frequently; reduce doses or interrupt treatment when needed.
• Kidney function: Monitor kidney function despite the lower nephrotoxicity risk.
• AUC-based dosing: GFR must be measured accurately and doses calculated carefully.

Important Pemetrexed Risks:

• Mucositis, fatigue, hematologic toxicity: Common adverse effects. Folic acid and vitamin B12 may reduce toxicity.
• Premedication is essential: Corticosteroids (dexamethasone) are given before and after treatment. Folic acid and vitamin B12 supplementation should start 7 days before treatment and continue throughout. Contraindicated with impaired kidney function (creatinine clearance <45 mL/min).

General Clinical Monitoring:

• Assess performance status (ECOG) regularly.
• Adverse effects, particularly grade 3 or higher toxicity, may require dose reduction, delay or discontinuation.
• Do not use during pregnancy or breastfeeding. Effective contraception is recommended.
• Assess electrolytes, kidney and liver function before each cycle.

Adverse Effects

The most common adverse effects of amivantamab (Rybrevant) + carboplatin + pemetrexed in lung cancer are based on clinical trial findings. Although each drug has specific adverse effects, common effects of the triple combination include:

• Low white blood cell count (leukopenia) 59%
• Nail redness, swelling, discoloration 56%
• Skin rash 54%
• Low red blood cell count (anemia) 50%
• Infusion reaction 42%
• Constipation 40%
• Nausea 36%
• Low platelet count 36%
• Loss of appetite 36%
• Acne-like (acneiform) rash 31%
• Arm and leg swelling (peripheral edema) 30%
• Mouth sores and inflammation (mucositis) 25%
• Diarrhea 21%
• Vomiting 21%
• Weakness, lack of strength 20%
• Fever 16%
• Fatigue 15%
• Cough 14%
• Neutropenic fever (fever + low white cell count) 3%